2023
Impact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study
See C, Wang Y, Huang H, Parise H, Yang Y, Tirziu D, Francese D, Papoutsidakis N, Bader E, Kaple R, Cleman M, Lansky A, Forrest J. Impact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study. Journal Of Interventional Cardiology 2023, 2023: 5390338. PMID: 37292113, PMCID: PMC10247319, DOI: 10.1155/2023/5390338.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementNew-onset conduction disturbancesAortic valve replacementPersistent conduction disturbancesConduction disturbancesValve replacementSurgical aortic valve replacementSingle-center retrospective analysisYale-New Haven HospitalSingle-center studyCause mortality ratesCause mortality riskLong-term outcomesNew Haven HospitalPeriprocedural factorsAortic stenosisConsecutive patientsTAVR proceduresTerm outcomesRetrospective analysisMortality riskMortality ratePatientsOutcomesPatient's ECG
2020
Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials.
Madhavan M, Bikdeli B, Redfors B, Biondi-Zoccai G, Varunok N, Burton J, Crowley A, Francese D, Gupta A, DER Nigoghossian C, Chatterjee S, Palmerini T, Benedetto U, You S, Ohman E, Kastrati A, Steg P, Gibson C, Angiolillo D, Krumholz H, Stone G. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardioangiologica 2020, 69: 398-407. PMID: 33258563, DOI: 10.23736/s2724-5683.20.05353-0.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeNetwork meta-analysisIncidence rate ratiosReceptor inhibitorsRandom-effects methodMeta-analysisCoronary syndromeMonths of follow-up timePatients of advanced ageControlled trialsBackground of aspirinEfficacy of prasugrelST-elevation myocardial infarctionCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsFollow-up timeFrequentist network meta-analysisManagement of patientsRegister of Controlled TrialsShort-term outcomesLong-term outcomesCochrane Central RegisterRandomized controlled trialsHemorrhagic outcomesAntiplatelet strategiesAntiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials
Madhavan MV, Bikdeli B, Redfors B, Biondi-Zoccai G, Varunok NJ, Burton JR, Crowley A, Francese DP, Gupta A, Der Nigoghossian C, Chatterjee S, Palmerini T, Benedetto U, You S, Ohman M, Kastrati A, Steg PG, Gibson C, Angiolillo DJ, Krumholz HM, Stone GW. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardioangiologica 2020 DOI: 10.23736/s0026-4725.20.05353-0.Peer-Reviewed Original ResearchSulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials
Bikdeli B, Chatterjee S, Kirtane AJ, Parikh SA, Andreozzi GM, Desai NR, Francese DP, Gibson CM, Piazza G, Goldhaber SZ, Eikelboom JW, Krumholz HM, Stone GW. Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars In Thrombosis And Hemostasis 2020, 46: 908-918. PMID: 33086402, DOI: 10.1055/s-0040-1716874.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisUse of sulodexideCause mortalityCardiovascular mortalityReduced oddsPulmonary embolismOdds ratioOdds of VTESafety of sulodexideCardiovascular risk factorsCochrane Central RegisterPeripheral arterial diseaseHistory of MIThrombotic cardiovascular diseasesRandom-effects modelCardiovascular efficacyOral glycosaminoglycansCardiovascular outcomesHemorrhagic eventsCentral RegisterVein thrombosisControlled TrialsArterial diseaseRandomized trialsRisk factorsPharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Group T. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis And Haemostasis 2020, 120: 1004-1024. PMID: 32473596, PMCID: PMC7516364, DOI: 10.1055/s-0040-1713152.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Subgroup of patientsCOVID-19 patientsFuture prospective studiesManagement of thrombosisSyndrome coronavirus 2Coronavirus disease 2019Mechanism of actionViral illnessThrombotic eventsRandomized trialsProspective studyAntithrombotic effectCoronavirus 2Antithrombotic agentsAntithrombotic drugsAntiviral effectDisease 2019Thrombotic diseaseAntithrombotic propertiesDosing approachWorldwide pandemicCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunction
2019
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology
Bikdeli B, McAndrew T, Crowley A, Chen S, Mehdipoor G, Redfors B, Liu Y, Zhang Z, Liu M, Zhang Y, Francese DP, Erlinge D, James SK, Han Y, Li Y, Kastrati A, Schüpke S, Stables RH, Shahzad A, Steg PG, Goldstein P, Frigoli E, Mehran R, Valgimigli M, Stone GW. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis And Haemostasis 2019, 120: 348-362. PMID: 31820428, PMCID: PMC7040882, DOI: 10.1055/s-0039-1700872.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAnticoagulantsData Interpretation, StatisticalDatabases, FactualDrug Administration ScheduleHeparinHirudinsHumansMedical InformaticsMyocardial InfarctionOutcome Assessment, Health CarePeptide FragmentsPercutaneous Coronary InterventionRandomized Controlled Trials as TopicRecombinant ProteinsRiskTreatment OutcomeConceptsPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionIndividual patient databaseProlonged bivalirudin infusionSegment elevation MIIndividual patient dataPatient-level dataDifferent relative risksConsensus-based definitionBivalirudin infusionPeriprocedural anticoagulationAnticoagulation regimenCoronary interventionElevation MIFemoral accessRandomized trialsPatient groupOutcome definitionsRelative riskPrespecified criteriaBivalirudinTrial publicationsST segmentPatient database
2017
Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters
Redfors B, Watson BM, McAndrew T, Palisaitis E, Francese DP, Razavi M, Safirstein J, Mehran R, Kirtane AJ, Généreux P. Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters. JAMA Cardiology 2017, 2: 798-802. PMID: 28315573, PMCID: PMC5815083, DOI: 10.1001/jamacardio.2017.0265.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlood TransfusionCardiac CathetersCase-Control StudiesCohort StudiesDatabases, FactualEndovascular ProceduresFemaleHealth Care CostsHeart-Assist DevicesHematomaHospital MortalityHumansIncidenceLength of StayLinear ModelsMaleMiddle AgedMortalityMultivariate AnalysisPostoperative HemorrhagePrognosisProsthesis ImplantationReoperationRetrospective StudiesTranscatheter Aortic Valve ReplacementUnited StatesConceptsLength of stayLarge-bore cathetersHealth care costsNational Inpatient Sample databaseTotal health care costsCare costsTranscatheter interventionsMedian total health care costsUtilization Project National Inpatient Sample databaseHigh mortalityPercutaneous left ventricular assist deviceTranscatheter aortic valve replacementLeft ventricular assist deviceLonger hospital stayAortic valve replacementRetrospective cohort studyEndovascular aneurysm repairMultivariable logistic regressionMultivariable linear regressionPercutaneous transcatheter interventionsVentricular assist deviceHospital mortalityProcedural bleedingHospital stayValve replacementImpact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction.
Redfors B, Palmerini T, Caixeta A, Ayele GM, Francese DP, Mehran R, Brilakis ES, Kirtane AJ, Karmpaliotis D, Stone GW, Généreux P. Impact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction. Journal Of Invasive Cardiology 2017, 29: 123-131. PMID: 28296639.Peer-Reviewed Original ResearchConceptsSYNTAX scoreChronic total occlusionNon-CTO lesionsCTO lesionsTotal occlusionUrgent Intervention Triage Strategy (ACUITY) trialComplex coronary artery diseaseMajor adverse cardiac eventsMedian SYNTAX scoreOverall SYNTAX scoreAdverse cardiac eventsCoronary artery diseaseAcute CatheterizationAngiographic substudyRevascularization scoresCardiac eventsRevascularization strategyArtery diseaseStrategy trialPatientsTraditional SSLesionsOutcome predictionRisk predictionSubstantial proportion
2016
Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents
Généreux P, Redfors B, Witzenbichler B, Arsenault MP, Weisz G, Stuckey TD, Rinaldi MJ, Neumann FJ, Metzger D, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Francese DP, Marquis-Gravel G, Mintz GS, Kirtane AJ, Maehara A, Mehran R, Stone GW. Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. International Journal Of Cardiology 2016, 231: 61-67. PMID: 28040289, DOI: 10.1016/j.ijcard.2016.12.150.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionDrug-eluting stentsPlatelet reactivityCoronary interventionIndependent predictorsDES PCILow residual platelet reactivityMajor adverse cardiac eventsSuccessful percutaneous coronary interventionContemporary percutaneous coronary interventionMultivariable logistic regression analysisCox proportional hazards modelDES generationADAPT-DES studyResidual platelet reactivityTarget lesion calcificationAdverse cardiac eventsPeripheral artery diseaseTwo-Year OutcomesKaplan-Meier curvesInsulin-treated diabetesCoronary arterial calcificationProportional hazards modelLogistic regression analysisAssociation of calcificationDedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches Outcomes From the Tryton Confirmatory Study
Généreux P, Kumsars I, Schneider JE, Lesiak M, Redfors B, Cornelis K, Selmon MR, Dens J, Hoye A, Metzger DC, Muyldermans L, Slagboom T, Francese DP, Ayele GM, Laak LL, Bartorelli AL, Cutlip DE, Kaplan AV, Leon MB. Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches Outcomes From the Tryton Confirmatory Study. JACC Cardiovascular Interventions 2016, 9: 1338-1346. PMID: 27388820, DOI: 10.1016/j.jcin.2016.03.042.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBiomarkersChromium AlloysCoronary AngiographyCoronary Artery DiseaseCoronary StenosisCoronary VesselsCreatine Kinase, MB FormEuropeFemaleHumansMaleMiddle AgedMyocardial InfarctionProspective StudiesProsthesis DesignRisk FactorsStentsTime FactorsTreatment OutcomeUnited StatesConceptsTryton Side Branch StentPeriprocedural myocardial infarctionSide Branch StentPivotal RCTsLarge side branchesPrimary endpointMyocardial infarctionBranch StentConfirmatory studiesBifurcation lesionsSide branchesProvisional side branchDedicated bifurcation stentsStent armOnly patientsAngiographic parametersCoronary artery bifurcationsPatientsRCTsSmall side branchesInfarctionOverall trialBifurcation stentsArtery bifurcationPre-defined performance goalSafety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level dataImpact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, Stone GW. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology 2016, 117: 1877-1883. PMID: 27131611, DOI: 10.1016/j.amjcard.2016.03.034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAspirinBlood PlateletsClopidogrelCoronary Artery DiseaseDrug Therapy, CombinationDrug-Eluting StentsEuropeFemaleHemorrhageHumansIncidenceMaleMiddle AgedMyocardial IschemiaPercutaneous Coronary InterventionPlatelet AggregationPlatelet Aggregation InhibitorsProspective StudiesRegistriesRisk AssessmentRisk FactorsSurvival RateTiclopidineUnited StatesConceptsHigh platelet reactivityDrug-Eluting Stents studyMajor adverse cardiac eventsAdverse cardiac eventsDual antiplatelet therapyPlatelet reactivityAntiplatelet therapyMajor bleedingCause mortalityCardiac eventsMultivariate adjustmentStent studiesWorld Health Organization criteriaImpact of anemiaPresence of anemiaPercutaneous coronary interventionDrug-eluting stentsIschemic riskBleeding riskClinical confoundersCoronary interventionAnemic patientsClinical outcomesHemoglobin levelsStudy cohortRelation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
Giustino G, Kirtane AJ, Généreux P, Baber U, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Dangas GD, Francese DP, Litherland C, Mehran R, Stone GW. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology 2016, 117: 1703-1713. PMID: 27067621, DOI: 10.1016/j.amjcard.2016.03.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood PlateletsCause of DeathCoronary ThrombosisDose-Response Relationship, DrugDrug Therapy, CombinationDrug-Eluting StentsFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet CountPostoperative HemorrhageProspective StudiesRisk FactorsSurvival RateTreatment OutcomeUnited StatesConceptsDrug-Eluting Stents studyDual antiplatelet therapyPlatelet countHigher platelet countsDrug-eluting stentsPlatelet reactivityAntiplatelet therapyMultivariable adjustmentThrombotic complicationsStent studiesHigh riskCoronary artery implantationResidual platelet reactivitySimple hematological parametersSpontaneous myocardial infarctionLow platelet countBleeding riskCause mortalityDES implantationCrude riskPlatelet inhibitionHemorrhagic riskRisk stratificationStudy cohortThrombotic eventsAngiographic predictors of 2‐year stent thrombosis in patients receiving drug‐eluting stents: Insights from the ADAPT‐DES study
Généreux P, Redfors B, Witzenbichler B, Maehara A, Yadav M, Weisz G, Francese DP, Parvataneni R, Brener SJ, Mehran R, Kirtane AJ, Stone GW. Angiographic predictors of 2‐year stent thrombosis in patients receiving drug‐eluting stents: Insights from the ADAPT‐DES study. Catheterization And Cardiovascular Interventions 2016, 89: 26-35. PMID: 26813732, DOI: 10.1002/ccd.26409.Peer-Reviewed Original ResearchMeSH KeywordsAgedCase-Control StudiesCoronary AngiographyCoronary Artery DiseaseCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleGermanyHumansMaleMiddle AgedMultivariate AnalysisPercutaneous Coronary InterventionPlatelet ActivationPlatelet Aggregation InhibitorsPlatelet Function TestsPredictive Value of TestsProportional Hazards ModelsProspective StudiesRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsADAPT-DES studyPercutaneous coronary interventionPresence of thrombusStent thrombosisDrug-eluting stentsAngiographic predictorsCardiology/American Heart Association type C lesionsCases of STIndependent angiographic core laboratoryIndex percutaneous coronary interventionMulticenter ADAPT-DES studyMultivariable Cox regression modelsSuccessful percutaneous coronary interventionDetailed angiographic analysisLong target lesionPre-specified analysisType C lesionsAcademic Research ConsortiumSaphenous vein graftsCox regression modelAngiographic core laboratoryADAPT-DESAngiographic variablesCoronary interventionSevere calcification
2015
Risk stratification of patients undergoing medical therapy after coronary angiography
Bettinger N, Palmerini T, Caixeta A, Dressler O, Litherland C, Francese DP, Giustino G, Mehran R, Leon MB, Stone GW, Généreux P. Risk stratification of patients undergoing medical therapy after coronary angiography. European Heart Journal 2015, 37: 3103-3110. PMID: 26685136, DOI: 10.1093/eurheartj/ehv674.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsCoronary artery diseaseSYNTAX scoreMedical therapyNSTE-ACSRisk stratificationSegment elevation acute coronary syndromesElevation acute coronary syndromeAdverse ischemic eventsMean SYNTAX scoreAdverse cardiac eventsAcute coronary syndromeBetter prognostic accuracyReceiver operator characteristic analysisImportant clinical implicationsStrongest predictorOperator characteristic analysisACUITY trialCoronary syndromeInitial angiogramCardiac eventsIschemic eventsPrognostic impactArtery diseaseCoronary angiographyReasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index.
Généreux P, Campos CM, Yadav M, Palmerini T, Caixeta A, Xu K, Francese DP, Dangas GD, Mehran R, Leon MB, Serruys PW, Stone GW. Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. EuroIntervention 2015, 11: 634-42. PMID: 25308300, DOI: 10.4244/eijy14m10_05.Peer-Reviewed Original ResearchMeSH KeywordsAgedArea Under CurveChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseDecision Support TechniquesFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPercutaneous Coronary InterventionPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsROC CurveTime FactorsTreatment OutcomeConceptsResidual SYNTAX scorePercutaneous coronary interventionBaseline SYNTAX scoreOne-year mortalityCoronary artery diseaseCAD burdenIncomplete revascularisationSYNTAX scoreCoronary interventionOne-year adverse outcomesResidual coronary artery diseaseNew prognostic instrumentPrediction of deathAngiograms of patientsBetter prognostic accuracyDegree of revascularisationACUITY trialArtery diseaseIndependent predictorsMultivariable analysisAdverse outcomesWorse outcomesPrognostic accuracyPrognostic instrumentPatientsOutcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study
Généreux P, Kini A, Lesiak M, Kumsars I, Fontos G, Slagboom T, Ungi I, Metzger DC, Wykrzykowska JJ, Stella PR, Bartorelli AL, Fearon WF, Lefèvre T, Feldman RL, Tarantini G, Bettinger N, Minalu Ayele G, LaSalle L, Francese DP, Onuma Y, Grundeken MJ, Garcia-Garcia HM, Laak LL, Cutlip DE, Kaplan AV, Serruys PW, Leon MB. Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study. Catheterization And Cardiovascular Interventions 2015, 87: 1231-1241. PMID: 26397982, DOI: 10.1002/ccd.26240.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery DiseaseCoronary StenosisCoronary ThrombosisFemaleHumansMaleMiddle AgedMyocardial InfarctionProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexSingle-Blind MethodStentsTime FactorsTreatment OutcomeConceptsPrimary end pointPercent diameter stenosisLarge side branchesBifurcation lesionsEnd pointDiameter stenosisMyocardial infarctionSegment percent diameter stenosisPeri-procedural myocardial infarctionAngiographic percent diameter stenosisSide branchesProvisional groupTarget vessel failureTarget vessel revascularizationTrue bifurcation lesionsComplex bifurcation lesionsNon-inferiority marginProvisional stenting strategyPrimary endpointVessel revascularizationTrial cohortCardiac deathTreatment strategiesProvisional stentingSB diameterIncidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention
Généreux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Yadav M, Francese DP, Palmerini T, Kirtane AJ, Litherland C, Mehran R, Stone GW. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. Journal Of The American College Of Cardiology 2015, 66: 1036-1045. PMID: 26314532, DOI: 10.1016/j.jacc.2015.06.1323.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCoronary Artery DiseaseDose-Response Relationship, DrugDrug Administration ScheduleDrug-Eluting StentsFollow-Up StudiesHumansMiddle AgedMultivariate AnalysisPatient DischargePercutaneous Coronary InterventionPlatelet AggregationPlatelet Aggregation InhibitorsPostoperative CarePostoperative HemorrhagePredictive Value of TestsProportional Hazards ModelsProspective StudiesRadiographyRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsPost-discharge bleedingPost-discharge myocardial infarctionPercutaneous coronary interventionSuccessful percutaneous coronary interventionADAPT-DES studyCause mortalityCoronary interventionChronic oral anticoagulation therapyDrug-eluting stent implantationCox proportional hazards regressionLower baseline hemoglobinSuccessful DES implantationUnrestricted patient populationOral anticoagulation therapyLow platelet reactivityProportional hazards regressionHigher crude ratesBaseline hemoglobinHospital survivorsAnticoagulation therapyGastrointestinal bleedingDES implantationHospital dischargeMultivariable adjustmentPrognostic impactThe association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial.
Madhavan MV, Généreux P, Palmerini T, Caixeta A, Xu K, McAndrew TC, Francese DP, Kirtane AJ, Mehran R, Stone GW. The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial. Journal Of Invasive Cardiology 2015, 27: 203-11. PMID: 25840404.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleHumansMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisPercutaneous Coronary InterventionPostoperative HemorrhageProportional Hazards ModelsProspective StudiesRandomized Controlled Trials as TopicRisk FactorsConceptsNon-ST segment elevation acute coronary syndromesPercutaneous coronary interventionCoronary artery diseaseExtent of CADMajor bleeding ratesSYNTAX scoreACUITY trialMajor bleedingCoronary interventionArtery diseaseBleeding rateSegment elevation acute coronary syndromesSeverity of CADElevation acute coronary syndromeSevere coronary artery diseaseAdverse ischemic eventsMajor bleeding eventsAcute coronary syndromeCommon risk factorsRecurrent adverse eventsBleeding eventsPCI cohortSS tertilesCoronary syndromeHemorrhagic events